Furthermore, analysis of 22 chordomas by Tamborini and co-workers showed consistent ERK1/2 activation in all the cases, and activation of AKT in 20 (91%), mTOR in 18 (82%), and S6 in 16 (73%) of the tumors [8]. The gene discussed is MAPK3; the disease is chordoma.